As global demand for gene therapy manufacturing soars, we’re seeing a growing strain on capacity, timelines, and reliability.
Between the rise in cell and gene therapy approvals and the surge of early-stage biotech companies pushing toward IND-enabling studies, one thing is becoming clear: access to fast, flexible, and high-quality viral vector production is no longer a luxury, it’s a bottleneck.
📈 According to a recent Endpoints News report, many biopharma leaders are re-evaluating partnerships due to rigid timelines and lack of transparency from large CDMOs. In parallel, GEN Edge recently highlighted how mid-sized, agile players are gaining traction by offering responsive service and custom manufacturing that actually meets the needs of today’s R&D teams.
That’s where we come in.
At Tailored Genes, we’ve spent over two decades building a reputation for precision, responsiveness, and scientific excellence in custom viral vector manufacturing and our new facility expansion in Vaughan is a direct answer to what the industry is calling for.
Here’s what’s changing and how we’re meeting the moment:
Industry Trend #1: Rise in Preclinical and IND-Enabling Programs Many early-stage biotech companies are moving quickly from discovery to preclinical work. What they need isn’t just scale — it’s customized vector production, rapid turnaround, and white-glove scientific support.
Our response: Expanded custom AAV and LVV manufacturing capacity, with shorter lead times, North American production, and full QC and analytical support, including full/empty capsid ratios, gene-specific titration, and sterility testing.
📉 Industry Trend #2: Overstretched CDMOs and Delays in Tech Transfers The “big box” manufacturing approach is showing cracks. Delays in tech transfer, a lack of visibility, and cookie-cutter approaches are slowing innovation.
✅ Our response: On-site scientific team with real-time consultation, plasmid design services, and stable cell line development tailored to your project’s biology, not just our batch schedule.
🌍 Industry Trend #3: Increased Focus on Domestic Manufacturing Supply chain concerns, regulatory preferences, and IP sensitivity are driving more biotechs to seek domestic partners.
✅ Our response: We’re proudly Canadian-owned and operated, offering GMP-aligned services and personalized project management right here in Ontario.
📣 The Bottom Line? If you’re scaling gene therapy research in 2025 and beyond, Tailored Genes is built for you. Our new site doesn’t just mean more space, it means more agility, more collaboration, and more ways to help you reach your milestones faster.
Ready to see what’s possible?
👉 Explore our capabilities 📩 Contact our team 📲 Follow us on LinkedIn for updates, insights, and behind-the-scenes content.
